Generics Maker Teva Pharmaceutical to Make Smaller Acquisitions, Chairman Says
Teva (TEVA), known for a series of large acquisitions that helped build its generic drug business, is now aiming mostly at smaller deals, the company’s chairman told Bloomberg.
TEVA Revenue TTM data by YCharts
Deals and a reliance on generics have helped Teva grow faster than some traditional pharmaceutical makers like Novartis (NVS), Pfizer (PFE), Merck (MRK) and Sanofi (SNY).
TEVA PE Ratio TTM data by YCharts
From the editors of YCharts, which includes the just-released YCharts Pro Platinum for professional investors.
Filed under: Company Analysis
Search Articles
Subscribe to YCharts Analysis
Recent Articles
View All
Company Analysis
View All
Company News
View All
Investing Ideas
View All
